TP53 mutant cell lines selected for resistance to MDM2 inhibitors retain growth inhibition by MAPK pathway inhibitors but a reduced apoptotic response

BACKGROUND: Emergence of resistance to molecular targeted therapy constitutes a limitation to clinical benefits in cancer treatment. Cross-resistance commonly happens with chemotherapeutic agents but might not with targeted agents. METHODS: In the current study, TP53 wild-type cell lines with drugga...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Cell Int
Main Authors: Wu, Chiao-En, Koay, Tsin Shue, Ho, Yi-Hsuan, Lovat, Penny, Lunec, John
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Primary Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6407233/
https://ncbi.nlm.nih.gov/pubmed/30899200
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0768-3
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items